N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and D-amphetamine-treated rats: Relevance to schizophrenia and bipolar disorder
Olivia M Dean, Maarten van den Buuse, Michael Berk, David L Copolov, Christine Mavros, Ashley I Bush
Neuroscience Letters | ELSEVIER IRELAND LTD | Published : 2011
This study was supported by funding from the Stanley Medical Research Institute, the Australian Research Council Federation Fellowship (to A.I.B.), the Woods Family Foundation (to A.I.B. and M.v.d.B.) and a research scholarship provided by the National Health and Medical Research Council (to O.M.D.). The authors greatly appreciate the technical assistance of Sally Martin.Dr. Berk has received grant or research support from Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, Novartis, Mayne Pharma, and Servier; is a consultant to Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck and Pfizer; and has been a speaker for Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Organon, Pfizer, Sanofi Synthelabo, Solvay and Wyeth. Dr. Bush is a shareholder and consultant for Prana Biotechnology Ltd, and a shareholder of Cogstate Ltd. Drs. Copolov, Berk and Bush are co-inventors on two provisional patents regarding the use of NAC and related compounds for psychiatric indications, assigned to the Mental Health Research Institute.